Good news: The FDA finally approved the Novavax Covid-19 vaccine.
Bad news: There are new restrictions that will create lots of problems for people who want to get the Novavax Covid-19 vaccine.
Good news: The FDA finally approved the Novavax Covid-19 vaccine.
Bad news: There are new restrictions that will create lots of problems for people who want to get the Novavax Covid-19 vaccine.
The new stricter criteria limits Novavax to people:
1. aged 65 and over
2. aged 12 and up who have at least one underlying condition that puts them at higher risk of severe illness
This goes against the science that indicates that everyone can benefit from Covid-19 vaccination.
Finally, the fact that the Trump administration delayed approval and restricted access to the Novavax Covid-19 vaccine — which is based on traditional vaccine technology — shows that questions raised about mRNA vaccines are disingenuous; they want to limit access to all vaccines.
FDA approval of the Novavax Covid-19 vaccine approval was delayed by 6 weeks, a clear sign of political interference that does not bode well for future vaccine approvals.
Also, issuing vaccine access restrictions based on risk profile makes it confusing about who qualifies, and many people who would otherwise get the vaccine may not try because they think they don't qualify.
Novavax and other Covid-19 vaccines should be approved for everyone.
The problem is that although the CDC lists many higher risk conditions, the FDA approval document is unclear about what qualifies as an underlying condition. This means many who should qualify may be wrongly turned away, and makes it less likely insurers will broadly cover Novavax.
Note: CDC lists many conditions that may make someone likelier to become severely ill with Covid-19, including older age, asthma, diabetes, lung disease, obesity and pregnancy.
By definition, most people are higher risk and should have access to Novavax.
https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html
GNU social JP is a social network, courtesy of GNU social JP管理人. It runs on GNU social, version 2.0.2-dev, available under the GNU Affero General Public License.
All GNU social JP content and data are available under the Creative Commons Attribution 3.0 license.